Vosevi Switzerland (Sofosbuvir/Velpatasvir/Voxilaprevir) 400mg Tablets | GLT

Generic Information: Vosevi — Gilead's Triple-Combination HCV Salvage Therapy, Switzerland Version

Vosevi is the fixed-dose triple combination developed and marketed by Gilead Sciences that brings together the three pillars of direct-acting antiviral (DAA) therapy in a single once-daily tablet: sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg. This page covers the Switzerland version — the original pack supplied for the Swiss market, released as 28 film-coated tablets (28 Filmtabletten / 28 comprimés pelliculés) with German and French labeling, and authorized in Switzerland under the marketing authorization holder Gilead Sciences Switzerland Sàrl, Steinhausen. The product was first approved by the FDA in 2017 as the "fourth-generation" Gilead hepatitis C regimen, positioned specifically for patients whose earlier DAA treatment did not achieve cure. The Swiss pack contains the same originator tablet at the same strengths as every other Vosevi presentation worldwide; what differs is the packaging language and the national authorization under which it is released.

What Is Vosevi Used For?

Vosevi occupies a very specific place in hepatitis C care: it is a salvage regimen. While newer patients are usually treated with simpler two-drug combinations, a meaningful minority of patients treated in the earlier DAA era — particularly those whose prior regimen included an NS5A inhibitor — failed to reach a sustained virologic response. For these treatment-experienced patients, Vosevi was designed to succeed where the previous course fell short. In the pivotal POLARIS-1 and POLARIS-4 studies, roughly 95%-97% of previously treated patients achieved SVR12 (cure, defined as undetectable virus 12 weeks after finishing therapy) across hepatitis C genotypes 1 through 6, without cirrhosis or with compensated cirrhosis. That performance made Vosevi the reference retreatment option internationally for DAA-experienced chronic hepatitis C.

How Does Vosevi Work?

The strength of this tablet comes from hitting the hepatitis C virus at three independent points of its life cycle at once. Sofosbuvir is a nucleotide analogue that the liver converts to its active form, which terminates the viral RNA chain as the genome is copied — a role no virus has so far escaped through resistance. Velpatasvir blocks the NS5A protein that organizes viral replication factories inside the host cell. Voxilaprevir inhibits the NS3/4A protease that cleaves the viral polyprotein into functional pieces. Because a prior NS5A-inhibitor failure typically reflects resistance mutations at NS5A rather than a general loss of susceptibility, adding the protease-inhibitor axis restores the ability to clear the virus even in patients carrying common NS5A resistance-associated substitutions. This complementary triple coverage is exactly why the regimen works as a rescue therapy rather than a first-line tablet.

Indications

Vosevi is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection, without cirrhosis or with compensated cirrhosis (Child-Pugh A), who have previously been treated with a DAA-containing regimen: either a regimen that included an NS5A inhibitor (any genotype 1-6), or a sofosbuvir-based regimen without an NS5A inhibitor for patients with genotype 1a or 3. It is not intended for decompensated liver disease, where other regimens are recommended.

Dosage

The recommended dose is one tablet once daily with food, for a fixed course of 12 weeks. Each tablet combines sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg, so no separate tablets or weight-based dosing are needed. A missed dose should be taken as soon as remembered the same day, but never doubled. No dose adjustment is required for mild or moderate renal impairment — including patients on dialysis — or for mild hepatic impairment. The regimen is not recommended in moderate to severe hepatic impairment (Child-Pugh B or C) because voxilaprevir exposure rises significantly. Prescribers must also screen for contraindicated co-medications before starting, since strong enzyme inducers and several common drugs are incompatible with this combination.

Side Effects

In the registration trials the regimen was remarkably well tolerated: fewer than one in four hundred patients discontinued treatment for adverse events. The most common side effects (reported in at least 10% of patients) were headache, fatigue, diarrhea, and nausea, generally mild to moderate and self-limited. Clinically important warnings include severe symptomatic bradycardia when amiodarone is taken together with sofosbuvir-containing regimens — amiodarone should be avoided — and reactivation of hepatitis B in coinfected patients, which requires monitoring before and during therapy. Efficacy of hormonal contraceptives containing ethinyl estradiol may be compromised, and rosuvastatin or dabigatran must not be co-administered.

Storage

Store the tablets below 30°C in the original container, tightly closed, protected from moisture. Keep out of reach of children and do not use after the expiry date printed on the pack.

Why Choose the GLT?

For patients and institutions seeking the original Gilead triple-therapy tablet, GLT offers the Switzerland version — genuine original packaging with German/French labeling released under Gilead Sciences Switzerland Sàrl — through a Hong Kong-licensed supply channel with full batch documentation. GLT serves both individual patients and institutional buyers (hospitals, clinics, pharmacies, and distributors), and can also supply the same molecule in other market presentations, giving buyers the flexibility to match the version to their documentation and budget requirements without leaving the originator product family.

How to Order Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)

To order the Switzerland version of Vosevi, contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Please specify the pack format (400 mg/100 mg/100 mg × 28 film-coated tablets), the quantity required, and the destination country, so we can confirm current stock, documentation, and delivery terms.

FAQ

Is the Switzerland version the same medicine as Vosevi sold elsewhere? Yes. It is the same Gilead-originator tablet with the same three active ingredients at the same strengths; the Swiss pack differs in language and in the national marketing authorization holder (Gilead Sciences Switzerland Sàrl, Steinhausen).

What does "DAA-experienced" or "salvage therapy" mean? It refers to patients who already completed a direct-acting antiviral course — often an older regimen containing an NS5A inhibitor — but whose virus came back or was never cleared. Vosevi is built specifically for this second-line situation.

How likely is Vosevi to cure hepatitis C after a failed prior treatment? In the key studies of previously treated patients, approximately 95%-97% achieved SVR12 across genotypes 1-6, which is considered a cure.

Do I need to review my current medications before starting? Absolutely. Amiodarone, rosuvastatin, dabigatran, ethinyl estradiol-containing products, and strong inducers such as rifampicin or certain antiepileptics are contraindicated or problematic — a full medication review is essential before the first dose.